Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Afamelanotide (Scenesse) demonstrated a moderate positive effect on skin photosensitivity in individuals with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with its efficacy comparable to inorganic sunscreen; however, organic sunscreens and various oral treatments (e.g., beta-carotene, vitamin C) showed no effect.
• The studies primarily focused on individuals with EPP or XLP, highlighting the relevance of these findings for this population, which experiences skin photosensitivity due to the accumulation of protoporphyrin IX (PPIX).
• The safety profile of afamelanotide (Scenesse) was noted as favorable; however, specific safety outcomes or adverse effects were not detailed in the study, indicating a lack of comprehensive safety data.
• No significant safety concerns or adverse effects were highlighted in the reviewed studies, particularly concerning individuals with EPP or XLP.
• The studies focused on individuals with EPP or XLP, demonstrating that afamelanotide effectively improves skin photosensitivity, which is particularly relevant for these populations due to the accumulation of PPIX.